PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.431
https://www.valueinhealthjournal.com/article/S1098-3015(19)32809-8/fulltext
Title :
PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32809-8&doi=10.1016/j.jval.2019.09.431
First page :
Section Title :
Open access? :
No
Section Order :
10356